The Top 5 Biosimilar Articles for the Week of July 19

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of July 19, 2021.

Number 5: Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.

Number 4: An advertisement for the Onpro wearable pegfilgrastim injector kit has the potential to undermine sales of biosimilars, the FDA stated in a warning letter.

Number 3: China approved a product for rheumatoid arthritis and Crohn disease that Mabpharm and Sorrento Therapteutics said is an improvement on infliximab.

Number 2: Amgen's advertising appeared to push doctors and patients away from the prefilled syringe version of its pegfilgrastim (Neulasta) product, which may have a better sales future than the Onpro.

Number 1: Just days after Bio-Thera announced initiation of a phase 3 study of patients receiving a candidate ustekinumab biosimilar, Samsung Bioepis said that it, too, began a phase 3 clinical trial for its own biosimilar version of the agent.

To read all of these articles and more, visit centerforbiosimilars.com.